Drug Policy Resources
Extensive research supports reforming our approach to drugs. Scroll down to browse our library of reports, academic studies, and other resources examining the harms of criminalization, harm-reduction strategies, and other related issues.
Harms of Criminalization
-
Study interviewed people who use drugs to obtain first-hand information about the impacts of drug laws and alternative approaches. “Participants openly and profoundly believed that current drug laws produced and propagated the public attitudes and structural inequities experienced by people who use drugs in Canada. This matters, not only because our findings highlight the fact that people who use drugs experience stigma in tangible and clearly impactful ways, but it also suggests that the criminlilization of drugs shapes the experience of structural, social, and self stigma. Finally, participants believed that efforts to destigmatize people who use drugs would be ineffectual without the enactment of more robust forms of drug law reform such as the decriminalization of illegal drugs.”
-
“This scoping review found an increased risk of drug-related death after release from prison, particularly during the first two weeks after release, though drug-related mortality risk remained elevated for the first year among former prisoners.” In the first 2 weeks post-release, opioid overdose deaths were 27 times higher than expected in the general population. In the first year post-release opioid overdose deaths were 15 times higher than observed in the general population.
-
The study found that police drug seizures were associated with increases in fatal overdose in the surrounding geographic area in the three weeks following enforcement, possibly by leading people with substance use disorder to take greater risks when they tried to restore their supply. The study, published in the American Journal of Public Health, raises questions about policies that might be exacerbating overdoses during a persistent epidemic that is contributing to reductions in the nation's life expectancy.
-
Despite large investments in and policy support for harm reduction including naloxone, syringes, and medications for opioid use disorder, people who use drugs continue to experience unprecedented rates of mortality from overdose and morbidity from infectious diseases. The criminalization of drug use has disproportionately exacerbated these drug-related harms and imposed short- and long-term burdens on already marginalized and vulnerable populations. Jeffrey P. Bratberg, Adrienne Simmons, Vibhuti Arya, Aneesha Bhatia, Sheila P. Vakharia. Support, don’t punish: Drug decriminalization is harm reduction. Journal of the American Pharmacists Association (Dec. 2022).
-
Comprehensive report on the impacts of policing on “people suffering physical and behavioral health problems” including lost educational opportunities, jobs, housing, and transportation — including impacts not only from violent interactions with police, but also from indirect exposure to routine policing activities. (Aaron Stagoff-Belfort, Daniel Bodah, and Daniela Gilbert, Vera Institute, November 2022)
-
This paper examines the ways that "drug war logic" has become embedded in key SDOH and systems, such as employment, education, housing, public benefits, family regulation (commonly referred to as the child welfare system), the drug treatment system, and the healthcare system.
-
Encounters with the criminal justice system can depress wages for the entirety of a career. Black and Latino Americans suffer these consequences most acutely. Craigie, Grawert, and Kimble. “Conviction, Imprisonment, and Lost Earnings: How Involvement with the Criminal Justice System Deepens Inequality.” Brennan Center (2020) (Click Here for Report)
-
Research finding that “traditional policing approach to drug use-related crime did not reduce arrests or incarceration and was associated with a risk of future overdose fatalities.” Zhang A, Balles JA, Nyland JE, Nguyen TH, White VM, Zgierska AE. The relationship between police contacts for drug use-related crime and future arrests, incarceration, and overdoses: a retrospective observational study highlighting the need to break the vicious cycle. Harm Reduct J. 2022 Jun 27;19(1):67.
-
Authors review “public health–oriented policy changes adopted to counter the ongoing overdose crisis (and suggest that they) are undercut by persistent structural racism and criminalization of people who use drugs, which work against that goal. We highlight 3 overarching barriers to GSL effectiveness: (1) provision of very limited protections, (2) implementation being subject to police discretion, and (3) presence of competing laws that further criminalize people who use illicit drugs.”
-
Essay by Nora D. Volkow, Director of the National Institute on Drug Abuse, explaining that “the perception of stigma by people with substance use disorders may cause them to avoid or delay engaging with health care or to conceal their drug use when interacting with health care professionals” and the “fear of possible criminal consequences for drug use can shape people’s health decision-making in many potentially deleterious ways.” (Nora D. Volkow, Stat, August 3, 2022)
-
Study finding that “Jail incarceration rates are potential drivers of many causes of death in US counties. Jail incarceration can be harmful not only to the health of individuals who are incarcerated, but also to public health more broadly.” Increases in jail incarceration rate were associated with increases in mortality from infectious diseases and chronic lower respiratory disease, an increases in mortality induced from substance use, suicide mortality, and from heart disease, unintentional injury, malignant neoplasm, diabetes, and cerebrovascular disease after 1 year. “Association between county jail incarceration and cause-specific county mortality in the USA, 1987–2017: a retrospective, longitudinal study.” Sandhya Kajeepeta, MS, Pia M Mauro, PhD, Katherine M Keyes, PhD, Abdulrahman M El-Sayed, MD, Caroline G Rutherford, BA, Seth J Prins, PhD. The Lancet, February 23, 2021.
-
Review of literature including 18 studies that were published in 2001 or later describing the relationship between incarceration history and overdose (“Recent evidence suggests that the leading cause of death after release from incarceration is unintentional poisoning (of which, OD is a type), with the highest risk occurring early after release (Binswanger et al., 2007; Massachusetts Department of Public Health, 2016; Merrall et al., 2010; Ranapurwala et al., 2018). An international meta-analysis of drug-related deaths after release identified a three-to eightfold increased risk in the first 2 weeks after release compared with subsequent two-week periods, up to the twelfth week (Merrall et al., 2010).”) (Sasha Mital, Jessica Wolff, Jennifer J.Carroll, Drug and Alcohol Dependence, August 1, 2020)
-
“Risk for drug-related death is significantly elevated in the 4 weeks following release from prison” (Waddell EN, Baker R, Hartung DM, Hildebran CJ, Nguyen T, Collins DM, Larsen JE, Stack E; ROAR Protocol Development Team. Reducing overdose after release from incarceration (ROAR): study protocol for an intervention to reduce risk of fatal and non-fatal opioid overdose among women after release from prison. Health Justice. 2020 Jul 10;8(1):18.)
-
Review of state eligibility restrictions for student financial aid for students with criminal legal system involvement. Identifying many state statutes excluding students with criminal history relating to drugs from eligibility for certain programs. (Education Commission of the States, 2020)
-
“People who inject drugs (PWID) are a medically and socially vulnerable population with a high incidence of overdose, mental illness, and infections like HIV and hepatitis C. Existing literature describes social and economic correlations to increased health risk, including stigma.” (Muncan, B., Walters, S.M., Ezell, J. et al. “They look at us like junkies”: influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City. Harm Reduct J 17, 53 (2020))
-
Study study aimed to identify changes in cocaine use associated with mandatory minimum sentencing policies by examining differential sentences for powder and crack cocaine set by the Anti-Drug Abuse Act (ADAA) (100:1) and the Fair Sentencing Act (FSA), which reduced the disparate sentencing to 18:1 and found that “(d)espite harsher ADAA penalties for crack compared to powder cocaine, there was no decrease in crack use following implementation of sentencing policies.” Walker, L.S., Mezuk, B. Mandatory minimum sentencing policies and cocaine use in the U.S., 1985–2013. BMC Int Health Hum Rights 18, 43 (2018). https://doi.org/10.1186/s12914-018-0182-2
-
The article discusses about the issues of the barriers to medications for addiction treatment. Stigma is a major driver behind the lack of access to opioid agonist therapy. Four factors which have been described as mediators of the stigma associated with medications for addiction treatment include the misconception that addiction is a willful choice, not a disease; the separation of addiction treatment from the rest of the medical system; the language that is used for addiction; and the way the criminal justice system does not incorporate medical judgment into its approach to people with addiction. Wakeman SE, Rich JD. Barriers to Medications for Addiction Treatment: How Stigma Kills. Subst Use Misuse. 2018 Jan 28;53(2):330-333.
-
Law review article detailing exclusion of people with drug offense histories from public housing. Schneider, Valerie, Indiana Law Journal, Spring (2018)
-
Law review article surveying laws applicable to the use of non-conviction records in employment and explaining how a record of incarceration or criminal justice involvement remains a barrier for individuals seeking employment. Geffen, Benjamin D., University of Pennsylvania Journal of Law and Social Change (2017).
-
A review of the public health and criminology literature and analysis of drug policies in the U.S. and abroad, providing evidence-based options for a new approach. (Click Here for Report)
-
Report detailing how criminalizing drug possession has caused dramatic and unnecessary harms in four states (Texas, Louisiana, Florida and New York) and around the country, both for individuals and for communities that are subject to discriminatory enforcement. (Click Here for More)
Overdose Prevention and Harm Reduction
-
A comprehensive review of the literature and evidence behind overdose prevention centers compiled by the Vermont Department of Health. (VDH, April 2024)
-
A guide to the best practices and key considerations for establishing an overdose prevention center, based on findings from focus groups across the USA. (DPA, 2024)
-
Compilation of evidence relating to overdose prevention centers. “Scientific Update on Overdose Prevention Centers: Annotated Bibliography 2022-2023. People Place & Health Collective and Drug Policy Alliance (2023)
-
This paper explored the impact of safer supply programs on injection practices from the perspective of clients and providers in Ontario, Canada. Authors concluded that “Safer supply programs can contribute to reducing injection-related health risks in addition to overdose risks. More specifically, they have the potential to address disease prevention and health promotion gaps that stand-alone downstream harm reduction interventions cannot address, by working upstream and providing a safer alternative to fentanyl.” Impact of safer supply programs on injection practices: client and provider experiences in Ontario, Canada. Marilou Gagnon, Katherine Rudzinski, Adrian Guta, Rose A. Schmidt, David T. Kryszajtys, Gillian Kolla & Carol Strike. Harm Reduction Journal volume 20, Article number: 81 (2023)
-
“Accumulating evidence has indicated that cannabis substitution is often used as a harm reduction strategy among people who use unregulated opioids (PWUO) and people living with chronic pain. (The study) sought to investigate the association between cannabis use to manage opioid cravings and self-reported changes in opioid use among structurally marginalized PWUO. . . (The) findings indicate that cannabis use to manage opioid cravings is a prevalent motivation for cannabis use among PWUO and is associated with self-assessed reductions in opioid use during periods of cannabis use. Increasing the accessibility of cannabis products for therapeutic use may be a useful supplementary strategy to mitigate exposure to unregulated opioids and associated harm during the ongoing drug toxicity crisis. ” Cannabis use to manage opioid cravings among people who use unregulated opioids during a drug toxicity crisis. Hudson Reddon, Stephanie Lake, Maria Eugenia Socias, Kanna Hayashi, Kora DeBeck, Zach Walsh, M-J Milloy. International Journal of Drug Policy, Volume 119, September 2023
-
Project focused on increasing education and awareness around xylazine in opioid user populations and primary care providers who work with these patients.
-
Opinion article with summary of evidence in support of Overdose Prevention Centers: “Supervised injection sites improve health outcomes. One study found a 26% net reduction in overdose deaths in the area surrounding a supervised injection site in Vancouver, Canada, compared with the rest of the city. A supervised injection site in Barcelona, Spain, was associated with a 50% reduction in overdose mortality from 1991 to 2008.”
-
Harocopos Alex, Brent E. Gibson, Nilova Sahal, Michael T. McRae, Kailin See, Sam Rivera, and Dave A. Chokshi. “First 2 Months of Operation at First Publicly Recognized Overdose Prevention Centers in US.” JAMA Network Open 5 (July 2022)
-
Research brief finding that “while overdose death rates have increased in every major demographic group in recent years, no group has seen a bigger increase than Black men. As a result, Black men have overtaken White men and are now on par with American Indian or Alaska Native men as the demographic groups most likely to die from overdoses.” (John Gramlich, Pew Research Institute, January 2022)
-
Study of an SCS, finding that each overdose that is managed at the SCS produced a benefit of $1622. The benefit of averting the cost of ambulance and emergency department care ranges between $39,739 and $74,612 per month, from November 2017 to January 2020, and that overall, there were $2,364,876 cost savings produced from the overdoses that were managed at the SCS site, by avoiding the need for ambulance and emergency department services. Also in 10% of clients were not coming to use drugs, many utilizing resources for other types of care and referrals. The number of people who frequent the SCS has increased, but the need for ambulance responses to overdoses have decreased. (Khair, Shahreen, Cathy A. Eastwood, Mingshan Lu, and Jennifer Jackson. 2022. “Supervised Consumption Site Enables Cost Savings by Avoiding Emergency Services: A Cost Analysis Study.” Harm Reduction Journal 19 (1): 32.)
-
Study finding that “People using the SCS were 27% less likely to visit the emergency department, had 54% fewer emergency department visits, were 32% less likely to be hospitalized, and spent 50% fewer nights in hospital.” (Lambdin, B.H., Davidson, P.J., Browne, E.N. et al. Reduced Emergency Department Visits and Hospitalisation with Use of an Unsanctioned Safe Consumption Site for Injection Drug Use in the United States. J GEN INTERN MED 37, 3853–3860 (2022))
-
Study finding that drug consumption rooms minimize skin and soft tissue infections among people who inject drugs because they provide sterile equipment, thus preventing reuse of materials. Also finding decreased emergency department visits. (Roux, P, M Jauffret-Roustide, C Donadille, L Briand Madrid, C Denis, I Célérier, C Chauvin, et al. 2022. “Impact of Drug Consumption Rooms on Non-Fatal Overdoses, Abscesses and Emergency Department Visits in People Who Inject Drugs in France: Results from the COSINUS Cohort.” International Journal of Epidemiology, June, 2022)
-
In July 2021, the Rhode Island government passed legislation supporting a two-year pilot program authorizing supervised consumption sites (SCSs) in response to the overdose crisis. This study estimated the costs and benefits of a hypothetical SCS in Providence, Rhode Island and found that SCS in would result in substantial cost savings due to prevention of costly emergency overdose care. (Laura C. Chambers, Benjamin D. Hallowell, Xiao Zang, David M. Rind, Greg F. Guzauskas, Ryan N. Hansen, Nathaniel Fuchs, Rachel P. Scagos, Brandon D.L. Marshall, “The estimated costs and benefits of a hypothetical supervised consumption site in Providence, Rhode Island,” International Journal of Drug Policy, Volume 108, 2022)
-
Study on barriers to implementing drug checking programs with additional evidence for use of such programs to prevent overdose (“Drug checking, or the use of technology to provide insight into the contents of illicit drug products, is an evidence-based strategy for overdose prevention.”) The Bronze Age of drug checking: barriers and facilitators to implementing advanced drug checking amidst police violence and COVID-19. Jennifer J. Carroll, Sarah Mackin, Clare Schmidt, Michelle McKenzie & Traci C. Green, Harm Reduction Journal volume 19, Article number: 9 (2022)
-
Journal article considering the “barriers to equitable drug checking services that impede population reach and distribution of services according to population need. Participants reported major barriers to access for themselves and others due to structural determinants including geography, criminalization, and stigma. Barriers also included lack of knowledge and cultural appropriateness of drug checking within certain communities, and individuals’ attitudes and behaviours around substance use and drug checking.”
-
This paper reviewed 22 studies about the impacts of SCSs on health and community outcomes, like overdose and crime rates. It found that “The strongest evidence suggests that SIFs may help reduce overdose morbidity and mortality and improve access to addiction treatment. An increase in crime, an often-cited concern of SIF opponents, was not observed to be associated with SIFs in most included studies, and crime was actually found to decrease in 2 studies.” (Levengood, Timothy W., Grace H. Yoon, Melissa J. Davoust, Shannon N. Ogden, Brandon D. L. Marshall, Sean R. Cahill, and Angela R. Bazzi. "Supervised Injection Facilities as Harm Reduction: A Systematic Review." American Journal of Preventive Medicine 61, no. 5 (2021): 738-749
-
Systematic review, which found that “monitoring of drug markets by drug checking services is well established in Europe and increasingly in North America; there is an emerging evidence base on the capacity of drug checking services to influence behavioural intention and, to a lesser extent, enacted behaviour, among people who use drugs.” (Maghsoudi, N, Tanguay, J, Scarfone, K, Rammohan, I, Ziegler, C, Werb, D, et al. Drug checking services for people who use drugs: a systematic review. Addiction. 2022; 117: 532– 544.)
-
Researchers “sought the perspectives of people involved in the unregulated drug market on how drug checking could be implemented as a market intervention within the current context of a highly unpredictable drug supply and unprecedented rates of overdose.” Findings suggest the need to prioritize trust and safety in the program design. (Bruce Wallace, Thea van Roode, Piotr Burek, Bernadette Pauly & Dennis Hore, Implementing drug checking as an illicit drug market intervention within the supply chain in a Canadian setting, Drugs: Education, Prevention and Policy (2022))
-
In response to a dramatic rise in overdose deaths due to injection drug use, there was a rapid scale-up of low-threshold supervised injection services (SIS), termed ‘overdose prevention sites’ (OPS), in Vancouver, Canada in December 2016. Researchers measured the potential impact of this intervention on SIS use and related health outcomes among people who inject drugs, and found that scaling up overdose prevention sites in Vancouver was associated with immediate and continued gradual increases in supervised injection service engagement and immediate increases in related health benefits. (Kennedy MC, Hayashi K, Milloy MJ, Compton M, Kerr T. Health impacts of a scale-up of supervised injection services in a Canadian setting: an interrupted time series analysis. Addiction. 2022 Apr;117(4):986-997.)
-
Kral, Alex H., Barrot H. Lambdin, Lynn D. Wenger, Erica N. Browne, Leslie W. Suen, and Peter J. Davidson. 2021. “Improved Syringe Disposal Practices Associated with Unsanctioned Safe Consumption Site Use: A Cohort Study of People Who Inject Drugs in the United States.” Drug and Alcohol Dependence. Available via Science Direct.
-
“Harm reduction services, which typically provide overdose education and prevention with distribution of naloxone and other supplies related to safer drug use, help reduce opioid-related overdose and infectious disease transmission. However, structural stigma and the ongoing criminalization of drug use have limited the expansion of harm reduction services into many non-urban communities in the United States that have been increasingly affected by the health consequences of opioid and polysubstance use.” Authors of the study “conducted qualitative interviews with 22 professionals working with people who use drugs in cities and towns across Rhode Island and Massachusetts to understand challenges and strategies for engaging communities in accepting harm reduction perspectives and services.” Implementing harm reduction in non-urban communities affected by opioids and polysubstance use: A qualitative study exploring challenges and mitigating strategies. E. Childs, K.B. Biello, P.K. Valente, P. Salhaney, D.L. Biancarelli, J. Olson, J.J. Earlywine, B.D.L. Marshall, A.R. Bazzi. International Journal of Drug Policy, Volume 90, April 2021.
-
Department of Health Report to explore the potential impact of incorporating overdose prevention centers into the City’s opioid response strategy. Based upon a literature review to summarize the international experience with OPCs and was developed in consultation with an Expert Advisory Panel comprised of national and international drug policy experts, scientists, and advocates was assembled to guide the study. NYC Health, 2018.
-
A review of literature pertaining to techniques, implementation models, and the benefits and risks associated with drug checking as a harm reduction intervention, with particular focus on existing drug checking services in other jurisdictions such as Western Europe. (British Columbia Centre on Substance Use, 2017)
-
A review by the Ontario Rapid Response Service of evidence about the effectiveness of safe injection sites (overdose prevention centers). (OHTN, 2014)
Vermont Reports and Resources
-
Annual snapshot of Vermont's criminal justice data to enable state leaders to respond from an evidence-based lens. (BJA & CSG, 2023)
-
Annual report by the Vermont Department of Health Vital Statistics System describing deaths of Vermonters occurring in-state and out-of-state during 2022, finding that there were 264 overdose deaths in Vermont during the year. Also contains data on overdose deaths resulting from all substances, including non-opioid drugs. More reports available at healthvermont.gov. Fatal Overdoses Among Vermonters Annual Data Brief – Data through 2022
-
In 2018, Vermont began providing MOUD for all incarcerated individuals with OUD statewide. In 2020, the COVID-19 state of emergency began. This study assessed the impact of both events on MOUD utilization and treatment outcomes. The study found “increased treatment engagement and a decrease in opioid-related overdose following implementation of MOUD in a statewide correctional system.”
-
“This paper evaluates the early impact of buprenorphine decriminalization in Vermont using a survey of Vermont residents who have recently used illicit opioids or recently participated in medication treatment for opioid use disorder. Importantly, our study gauges perceptions of state decriminalization of buprenorphine and changes in nonprescribed buprenorphine use or diversion among the population the policy is intended to impact.”
-
Council of State Governments Justice Center Report (April 2022): “Justice Reinvestment in Vermont Results of Racial Equity in Sentencing Analysis” (Finding that “when similarly situated Black and White defendants are compared . . . racial disparities are seen within felony property and felony drug offenses, where Black people are 18 percentage points more likely to receive an incarceration sentence than comparable White people.”)
-
Annual report by Vermont Department of Health Vital Statistics System describing deaths of Vermonters occurring in-state and out-of-state (preliminary 2021 opioid-related accidental and undetermined fatal overdose data showing a 33% increase in opioid-related fatal overdoses from 2021
-
Visualizations showing the estimated overdose deaths in each county as of 2018, as retrieved from the Centers for Disease Control and Prevention in fall 2020 and jail data from the Bureau of Justice Statistics, as compiled by Vera Trends as of September 2020. (Click Here to Read More)
-
“Many states now require law enforcement to collect race data on traffic stops, but there has been little research on the use of that data to inform public policy or reform efforts at the agency level. This article addresses that lacuna by presenting results from the first statewide analysis of Vermont traffic stop data. Racial threat theory, a subset of stratification theory, would predict that policing in a predominantly white state like Vermont would exhibit lower racial disparities than states with a more racially diverse population because the “threat” to white dominance is less. The results contradict that prediction. Vermont, despite its reputation as a liberal state, is not different from other states in exhibiting wide racial disparities in policing. And yet, analysis and dissemination of race data in policing, by providing an evidentiary basis for citizen claims of racial bias, contributed to action on the part of the state legislature and government to address racial discrimination not only in policing but also in the broader criminal justice system. We report on those reform efforts and on the actions taken by three reform-minded law enforcement agencies to reduce and eliminate unjustifiable racial disparities in policing.” Driving While Black and Brown in Vermont: Can Race Data Analysis Contribute to Reform?, Stephanie Seguino and Nancy Brooks, The Review of Black Political Economy, Volume 48, Issue 1, Nov. 16, 2020
-
Data brief produced by the Vermont Department of Health reviewing the role of xylazine in fatal drug overdoses. (Department of Health, October 2021)
-
Short report including data on rate of people receiving Medication Assisted Treatment (MAT) for opioid use disorders in Vermont. (Department of Health, January 2021)
-
Decriminalization of Diverted Buprenorphine in Burlington, Vermont and Philadelphia: An Intervention to Reduce Opioid Overdose Deaths, Brandon del Pozo, Postdoctoral Fellow, Lawrence S. Krasner, and Sarah F. George (June 2020)
-
Offers a list of policy options for continued reform efforts, including drug decriminalization, expanding alternatives to incarceration, investing in treatment for mental health and substance-use conditions, and reforms in Vermont’s bail, sentencing, and parole systems. (ACLU-VT, 2019)
Decriminalization
-
In this cohort study of fatal overdose and fentanyl spread through Oregon’s unregulated drug market, decriminalization of drug possession was not associated with an increase in fatal drug overdose rates in Oregon in the 2 years after its enactment. (JAMA Network Open, 2024)
-
Paper analyzing the provisions of Measure 110, its early impacts, successes, and challenges, and outlining lessons that jurisdictions contemplating decriminalizing drug possession in the U.S. and globally should consider. Russoniello K, Vakharia SP, Netherland J, et al. Decriminalization of drug possession in Oregon: Analysis and early lessons. Drug Science, Policy and Law. 2023
-
Briefing updating 2016 report on Portugal's reforms, and marking the 20th anniversary of their introduction in Portugal. (Transform Drug Policy Foundation, May 2021)
-
Initial research investigating impacts of Oregon’s measure 110 examining publicly available calls for service data after Ballot Measure 110’s implementation. (Preliminary analysis, August 2022)
-
Review of the literature on depenalization, diversion, and decriminalization, which found evidence that these alternative policies do not increase the scale of violence of organized crime and that some alternatives in some contexts can reduce health and crime harms. Stevens, A., Hughes, C. E., Hulme, S., & Cassidy, R., European Journal of Criminology, 19(1), 29–54 (2022)
-
A resource for people from all sectors who wish to understand the key objectives, principles and concepts relating to decriminalisation of drug use and how to advocate for it. (IDPC, February 2022)
-
Paper providing a practical framework that can be used to deliberate on potential reform decisions. Greer A, Bonn M, Shane C, Stevens A, Tousenard N, Ritter A. (Int J Drug Policy. 2022)
-
Vancouver’s proposal to Federal government for emergency exemption under 56(1) of the Controlled Drugs and Substances Act (CDSA) that would decriminalize personal possession of illicit substances within the City’s boundaries. (May 28, 2021)
-
Report from the Health Canada Expert Task Force on Substance Use on alternatives to criminal penalties for simple possession of controlled substances concluding “that criminalization of simple possession causes harms to Canadians and needs to end.” (Health Canada, May 6, 2021)
-
Report presenting findings from an evaluation of criminal legal policy reforms impacting vulnerable populations in Baltimore City, conducted by researchers from the Johns Hopkins Bloomberg School of Public Health. (Susan G. Sherman, PhD, MPH, Saba Rouhani, PhD, MSc Catherine Tomko, PhD, MHS, Noelle P. Weicker, MHS, October 2021)
-
Study from California after the passing of Prop 47 on the impact of the defelonization of personal use drug possession on recidivism rates. (2020)
-
Report published by the Narkotika Politiskt Center attempting to “give the best possible picture of the huge efforts undertaken in Portugal at the beginning of the 21st century and the way in which the situation has developed since.” Also contains a brief overview of another ten countries in Europe which have decriminalised drugs.
-
“In June of 2018… the chief of police of Burlington, Vermont, and the state’s attorney who prosecutes Burlington’s criminal cases, announced that (they) would not arrest or prosecute people for misdemeanor possession of unprescribed buprenorphine, the partial agonist medication shown to be highly effective at treating opioid use disorder (OUD). (They) were the first public officials in the United States to de facto decriminalize the possession of a controlled substance in response to the nation’s opioid crisis. This article explains the rationale for the policies.
-
Drug Policy Alliance Report on Decriminalization in Portugal describing reduction in overdose deaths, HIV infections and incarceration following enactment of drug decriminalization in 2001
-
“A growing body of evidence suggests that decriminalization is an effective way to mitigate the harms of substance use and the policies and practices used to deal with it. This policy brief reviews the various ways in which decriminalization of controlled substances is being interpreted and implemented internationally and in Canada. (Canadian Centre on Substance Use and Addiction, June 2018)
-
A review of the public health and criminology literature and analysis of drug policies in the U.S. and abroad, providing evidence-based options for a new approach. (Click Here for Report)
-
Second edition of ‘A Quiet Revolution: Drug Decriminalisation Across the Globe’, building on initial report published in 2012 and providing updates on the jurisdictions originally covered and highlighting new countries that have adopted a non-criminal justice response to the possession of drugs for personal use. (Release, 2016)
-
Report reviewing the evidence in 21 countries that have adopted some form of decriminalization and has found that the model of enforcement adopted has little impact on the rates of drug use in a country. (Release, 2012)